Detection of minimal residual disease

Methods in Cell Biology

Volumn 64, Issue 64, 2001, Pages 385-420

  Deptala, Andrzej ^a,b   Mayer, Sharon P ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ARTICLE; BONE MARROW EXAMINATION; CYTOGENETICS; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA; LYMPH NODE; LYMPHOMA; METABOLISM; METHODOLOGY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; REMISSION;

BONE MARROW EXAMINATION; CYTOGENETICS; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA; LYMPH NODES; LYMPHOMA; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION; REMISSION INDUCTION; TUMOR MARKERS, BIOLOGICAL;

EID: 0035219813     PISSN: 0091679X     EISSN: None     Source Type: Book Series    
DOI: 10.1016/s0091-679x(01)64023-8     Document Type: Article

References (79)

1. Anastasi, J. (1993). Fluorescence in situ hybridization in leukemia. Applications in diagnosis, subclassification, and monitoring the response to therapy. Ann. N.Y. Acad. Sci. 677, 214-224.
2. Behm, F. G., Smith, F. O., Raimondi, S. C., Pui, C. H., and Bernstein, I. D. (1996). Human homologue of the rat chondroitin sulfate proteoglycan NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. Blood 87, 1134-1139.
3. Bose, S., Deninger, M., Gora-Tybor, J., Goldman, J. M., and Melo, J. V. (1998). The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: Biologic significance and implications for the assessment of minimal residual disease. Blood 92, 3362-3367.
4. Campana, D. (1994). Applications of cytometry to study acute leukemia: In vitro determination of drug sensitivity and detection of minimal residual disease. Cytometry 18, 68-74.
5. Campana, D. and Pui, C. H. (1995). Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 85, 1416-1434.
6. Cavé, H., van der Werff ten Bosch, J., Suciu, S., Guidal, C., Waterkeyn, C., Otten, J., Bakkus, M., Thielemans, K., Grandchamp, B., and Vilmer, E. (1998). Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer- Childhood Leukemia Cooperative Group. N. Engl. J. Med. 339, 591-598.
7. Chim, J. C., Coyle, L. A, Yaxley, J. C., Cole-Sinclair, M. F., Cannell, P. K., Hoffbrand, V. A., and Foroni, L. (1996). The use of IgH fingerprinting and ASO-dependent PCR for the investigation of residual disease (MRD) in ALL. Br. J. Haematol. 92, 104-115.
8. Cole-Sinclair, M., Foroni, L., and Hoffbrand, V. A. (1994). Genetic changes: Relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukemia. Bailliére's Clin. Haematol. 7, 183-233.
9. Coustan-Smith, E., Behm, F. G., Sanchez, J., Boyett, J. M., Hancock, M. L., Raimondi, S. C., Rubnitz, J. E., Rivera, G. K., Sandlund, J. T., Pui, C. H., and Campana, D. (1998). Immunological detection of minimal residual disease in children with acute lymphoblastic leukemia. Lancet 351, 550-554.
10. Cross, N. C., Feng, L., Chase, A., Bungey, J., Hughes, T. P., and Goldman, J. M. (1993). Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 82, 1929-1936.
11. Darzynkiewicz, Z., Robinson, J. P., and Crissman, H. A. (eds.) (1994). "Methods in Cell Biology: Flow Cytometry" 2nd Ed., Parts A and B, Vols. 41 and 42. Academic Press, San Diego.
12. Deptala, A. (1995). The significance of immunophenotyping in detection of minimal residual disease in acute leukemias. Doctoral thesis, Warsaw Medical University, Warsaw, Poland (in Polish).
13. Deptala, A., Widzyńska, I., and Kuratowska, Z. (1995a): Clinical significance and prognosis in acute leukemias because of the detection of minimal residual disease. Acta Haematol. Pol. 26, 413-420 (in Polish).
14. Deptala, A., Widzyńska, I., and Kuratowska, Z. (1995b). Immunophenotyping of bone marrow cells detects minimal residual disease in acute leukemias. Acta Haematol. Pol. 26, 403-411 (in Polish).
15. Dibenedetto, S. P., Lo Nigro, L., Mayer, S. P., Rovera, G., and Schiliro, G. (1997). Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. Blood 90, 1226-1232.
16. Drach, J., Drach, D., Glassl, H., Gattringer, G., and Huber, H. (1992). Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. Cytometry 13, 893-901.
17. Drexler, H. G., Borkhardt, A., and Janssen, J. W. (1995). Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Leukemia-Lymphoma 19, 359-380.
18. Engel, H., Drach, J., Keyhani, A., Jiang, S., Van, N. T., Kimmel, M., Sanchez-Williams, G., Goodacre, A., and Andreef, M. (1999). Quantitation of minimal residual disease in acute myelogenous leukemia and myelodysplastic syndromes in complete remission by molecular cytogenetics of progenitor cells. Leukemia 13, 568-577.
19. Estrov, Z., Grunberger, T., Dubé, I. D., Wang, Y.-P., and Freedman, M. H. (1986). Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N. Engl. J. Med. 315, 538-542.
20. Estrov, Z., Ouspenskaia, M. V., Felix, E. A., McClain, K. L., Lee, M.-S., Harris, D., Pinkel, D. P., and Zipf, T. F. (1994). Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia 8, 46-51.
21. Evans, P. A. S., Short, M. A., Jack, A. S., Norfolk, D. R., Child, J. A., Shiach, C. R., Davies, F., Tobal, K., Liu Yin, J. A., and Morgan, G. J. (1997). Detection and quantitation of the CBFβ/ MYH11 transcripts associated with the inv(16) in presentation and follow-up samples from patients with AML. Leukemia 11, 364-369.
22. Evans, P. A. S., Short, M. A., Owen, R. G., Jack, A. S., Forsyth, P. D., Shiach, C. R., Kinsey, S., and Morgan, G. J. (1998). Residual disease detection using fluorescent polymerase chain reaction at 20 weeks of therapy predicts clinical outcome in childhood acute lymphoblastic leukemia. J. Clin. Onco. 16, 3616-3627.
23. Farahat, N., Lens, D., Zomas, A., Morilla, R., Matutes, E., and Catovsky, D. (1995). Quantitative flow cytometry can distinguish between normal and leukaemic B-cell precursors. Br. J. Haematol. 91, 640-646.
24. Fischer, H., Hindkjaer, J., Pedersen, S., Koch, J., Brandt, C., and Kølvraa, S. (1994). Primed in situ labeling (PRINS) and fluorescence in situ hybridization (FISH). In "Methods in Cell Biology: Flow Cytometry" (Z. Darzynkiewicz, J. P. Robinson, and H. A. Crissman, eds.), 2nd Ed., Part B, Vol. 42, pp. 72-93. Academic Press, San Diego.
25. Freireich, E. J., Cork, A., Stass, S. A., McCredie, K. B., Keating, M. J., Estey, E. H., Kantarjian, H. M., and Trujillo, J.M. (1993). Cytogenetics for detection of minimal residual disease in acute myelogenous leukemia. Leukemia 7, 736-741.
26. Galoin, S., al Saati, T., Schleifer, D., Huynh, A., Attal, M., and Delsol, G. (1996). Oligonucleotide clonospecific probes directed against the junctional sequence of t(14;18): A new tool for the assessment of minimal residual disease in follicular lymphomas. Br. J. Haematol. 4, 676-684.
27. Gray, J. W., Kuo, W. L., Liang, J., Pinkel, D., van den Engh, G., Trask, B., Tkachuk, D., Waldman, F., and Westbrook C. (1990). Analytical approaches to detection and characterization of disease-linked chromosome aberration. Bone Marrow Transpl. 6(Suppl. 1), 14-19.
28. Greaves, M. F., Chan, L. C., Furley, A. J. W., Watt, S. M., and Molgaard, H. V. (1986). Lineage promiscuity in hemopoietic differentiation and leukemia. Blood 67, 1-11.
29. Groeneveld, K., te Marvelde, J. G., van den Beemd, M. W. M., Hooijkaas, H., and van Dongen, J. J. M. (1996). Flow cytometric detection of intracellular antigens for immunophenotyping of normal and malignant leukocytes. Leukemia 10, 1383-1389.
30. Gross, H. J., Verwer, B., Houck, D., and Recktenwald, D. (1993). Detection of rare cells at a frequency of one per million by flow cytometry. Cytometry 14, 519-526.
31. (-7). Proc. Natl. Acad. Sci. U.S.A. 92, 537-541.
32. Hittelman, W. N., Tigaud, J. D., Estey, E., and Vadhan-Raj, S. (1990). Premature chromosome condensation in the study of minimal residual disease. Bone Marrow Transpl. 6(Suppl. 1), 9-13.
33. Ito, Y., Wasserman, R., Galili, N., Reichard, B. A., Shane, S., Lange, B., and Rovera, G. (1993). Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acute lymphoblastic leukemia. J. Clin. Oncol. 11, 546-553.
34. Jennings, C. D. and Foon, K. A. (1997). Recent advances in flow cytometry: Application to the diagnosis of hematologic malignancy. Blood 90, 2863-2892.
35. Kasprzyk, A. and Seeker-Walker, L. M. (1997). Increased sensitivity of minimal residual disease detection by interphase FISH in acute lymphoblastic leukemia with hyperdiploidy. Leukemia 11, 429-435.
36. Kishimoto, T., Goyert, S., Kikutani, H., Mason, D., Miyasaka, M., Moretta, L., Ohno, T., Okumura, K., Shaw, S., Springer, T. A., Sugamura K., Sugawara, H., von dem Borne, A. E. G. K., and Zola, H. (1997). Update: New CD antigens, 1996. Tissue Antigens 49, 287-288.
37. Knapp, W., Strobl, H., and Majdic, O. (1994). Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. Cytometry 18, 187-198.
38. Kurokawa, T., Kinoshita, T., Ito, T., Saito, H., and Hotta, T. (1996). Detection of minimal residual disease B cell lymphoma by a PCR-mediated RNase protection assay. Leukemia 10, 1222-1231.
39. Lanza, F., Castoldi, G. L., Castagnari, B., Todd, R. F., Moretti, S., Spisani, S., Latorraca, A., Focarile, E., Roberti, M. G., and Traniello, S. (1998). Expression and functional role of urokinase-type plasminogen activator receptor in normal and acute leukaemic cells. Br. J. Haematol. 103, 110-123.
40. Lavabre-Bertrand, T., Janossy, G., Ivory, K., Peters, R., Seeker-Walker, L., and Porwitt-MacDonald, A. (1994). Leukemia-associated changes identified by quantitative flow cytometry: I. CD10 expression. Cytometry 18, 209-217.
41. Lin, F., van Rhee, F., Goldman, J. M., and Cross, N. C. (1996). Kinetics of increasing BCR-ABL transcript numbers in chronic myeloid leukemia patients who relapse after bone marrow transplantation. Blood 87, 4473-4478.
42. Liu, P., Tarle, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., and Collins, F. S. (1993). Fusion between transcription factor CBFβ/PEBP2β and a myosin heavy chain in acute myeloid leukemia. Science 261, 1041-1044.
43. Macedo, A., Orfao, A., Gonzalez, M., Vidriales, M. B., Lopez-Berges, M. C., Martinez, A., and San Miguel, J. F. (1995). Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: Implications for minimal residual disease studies. Leukemia 9, 993-998.
44. Macedo, A., Orfao, A., Ciudad, J., Gonzalez, M., Vidriales, B., Lopez-Berges, M. C., Martinez, A., Landolfi, C., Canizo, C., and San Miguel, J. F. (1995). Phenotypic analysis of CD34 subpopulations in normal human bone marrow and its application for the detection of minimal residual disease. Leukemia 9, 1896-1901.
45. Marcucci, G., Livak, K. J., Bi, W., Strout, M. P., Bloomfield, C. D., and Caligiuri, M. A. (1998). Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay. Leukemia 12, 1482-1489.
46. Mayer, S. P., Giamelli, J., Sandoval, C., Roach, A. S., Ozkaynak, M. F., Tugal, O., Rovera, G., and Jayabose, D. (1999). Quantitation of leukemia clone-specific antigen gene rearrangements by a single-step PCR and fluorescence-based detection method. Leukemia 13, 1843-1852.
47. Mensink, E., van de Locht, A., Schattenberg, A., Linders, E., Schaap, N., Geurts van Kessel, A., and De Witte, T. (1998). Quantitation of minimal residual disease in Philadelphia chromosome positive chronic myeloid leukemia patients using real-time quantitative RT-PCR. Br. J. Haematol. 102, 768-774.
48. Moravcová, J., Lukasova, M., Stary, J., and Haskovec, C. (1998). Simple competitive two-step RT-PCR assay to monitor minimal residual disease in CML patients after bone marrow transplantation. Leukemia 12, 1303-1312.
49. Mori, T., Sugita, K., Suzuki, T., Okazaki, T., Manabe, A., Hosoya, R., Mizutani, S., Kinoshita, A., and Nakazawa, S. (1995). A novel monoclonal antibody, KOR-SA3544 which reacts to Philadelphia chromosome-positive acute lymphoblastic leukemia cells with high sensitivity. Leukemia 9, 1233-1239.
50. Nagai, J., Kigasawa, H., Tomioka, K., Koga, N., Nishihira, H., and Nagao, T. (1994). Immunocytochemical detection of bone marrow-invasive neuroblastoma cells. Eur. J. Haematol. 53, 74-77.
51. Nakao, M., Yokota, S., Horiike, S., Taniwaki, M., Kashima, K., Sonoda, Y., Koizumi, S., Takaue, Y., Matsushita, T., Fujimoto, T., and Misawa, S. (1996). Detection and quantification of TEL/ AML1 fusion transcripts by polymerase chain reaction in childhood acute lymphoblastic leukemia. Leukemia 10, 1463-1470.
52. Nakao, M., Janssen, J. W., Flohr, T., and Bartram, C. R. (2000). Rapid and reliable quantification of minimal residual disease in acute lymphoblastic leukemia using rearranged immunoglobulin and T-cell receptor loci by LightCycler technology. Cancer Res. 60, 3281-3289.
53. Nowak, R., Oelschlaegel, U., Schuler, U., Zengler, H., Hofmann, R., Ehninger, G., and Andreeff, M. (1997). Sensitivity of combined DNA/immunophenotype flow cytometry for the detection of low levels of aneuploid lymphoblastic leukemia cells in bone marrow. Cytometry 30, 47-53.
54. Ouspenskaia, M. V., Johnston, D. A., Roberts, W. M., Estrov, Z., and Zipf, T. F. (1995). Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: A description of the methods and principles involved. Leukemia 9, 321-328.
55. Pelkey, T. J., Frieson, H. F., and Bruns, D. E. (1996). Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors. Clin. Chem. 42, 1369-1381.
56. Pongers-Willemse, M. J., Verhagen, O. J. H. M., Tibbe, G. J. M., Wijkhuijs, A. J. M., de Haas, V., Roovers, E., and van der Schoot, C. E. (1998). Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional regional specific TaqMan probes. Leukemia 12, 2006-2014.
57. Porwitt-MacDonald, A. T., Janossy, G., Ivory, K., Swirsky, D., Peters, R., Wheatly, K., Walker, H., Turker, A., Goldstone, A. H., and Burnett, A. (1996). Leukemia-associated changes identified by quantitative flow cytometry: IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). Blood 87, 1162-1169.
58. Roberts, W. M., Estrov, Z., Ouspenskaia, M. V., Johnston, D. A., McClain, K. L., and Zipf, T. F. (1997). Measurement of residual leukemia during remission in childhood acute lymphoblastic leukemia. N. Engl. J. Med. 336, 317-323.
59. Ross, A. A. (1998). Minimal residual disease in solid tumor malignancies: A review. J. Hematother. 7, 9-18.
60. Sandoval, C., Mayer, S. P., Giamelli, J., Farley, T., Ozkaynak, M. F., Tugal, O., and Jayabose, S. (2000). Cytogenetic abnormalities during clinical, immunophenotypic, and molecular remission in pediatric acute lymphoblastic leukemia. Cancer Genet. Cytogenet. 118, 9-13.
61. Sang, B. C., Shi, L., Dias, P., Liu, L., Wei, J., Wang, Z. X., Monell, C. R., Behm, F., and Gruenwald, S. (1997). Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: Characterization and diagnostic utility. Blood 89, 2909-2914.
62. Satake, N., Kobayashi, H., Tsunematsu, Y., Kawasaki, H., Horikoshi, Y., Koizumi, S., and Kaneko, Y. (1997). Minimal residual disease with TEL-AML1 fusion transcript in childhood acute lymphoblastic leukaemia with t(12;21). Br. J. Haematol. 97, 607-611.
63. Sawyers, C. L. (1998). Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes. Leukemia Res. 22, 1113-1122.
64. Schoenfeld, A., Kruger, K. H., Gomm, J., Sinnett, H. D., Gazet, J. C., Sacks, N., Bender, H. G., Luqmani, Y., and Coombes, R. C. (1997). The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19. Eur. J. Cancer 33, 854-861.
65. Seale, R. C., Varma, S., Swirsky, D. M., Pandolfi, P.-P., Goldman, J. M., and Cross, N. C. P. (1996). Quantification of PML-RARα transcripts in acute promyelocytic leukaemia: Explanation for the lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of the leukaemia-specific mRNA by a interferon. Br. J. Haematol. 95, 95-101.
66. Sinclair, P. B., Green, A. R., Grace, C., and Nacheva, E. P. (1997). Improved sensitivity of BCR-ABL detection: A triple-probe three-color fluorescence in situ hybridization system. Blood 90, 1395-1402.
67. Steward, C. G., Goulden, N. J., Katz, F., Baines, D., Martin, P. G., Langlands, K., Potter, J. M., Chessells, J. M., and Oakhill, A. (1994). A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor δ gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood 83, 1355-1362.
68. Stewart, C. C. and Stewart, S. J. (1994a). Cell preparation for the identification of leukocytes. In "Methods in Cell Biology: Flow Cytometry" (Z. Darzynkiewicz, J. P. Robinson, and H.A. Crissman, eds.), 2nd Ed., Part A, Vol. 41. Academic Press, San Diego.
69. Stewart, C. C. and Stewart, S. J. (1994b). Multiparameter analysis of leukocytes by flow cytometry. In "Methods in Cell Biology: Flow Cytometry" (Z. Darzynkiewick, J. P. Robinson, and H. A. Crissman, eds.), 2nd Ed., Part A, Vol. 41. Academic Press, San Diego.
70. Tobal, K. and Liu Yin, J. A. (1998). RT-PCR method with increased sensitivity shows persistence of PML-RARA fusion transcripts in patients in long-term remission of APL. Leukemia 12, 1349-1354.
71. Tobal, K., Johnson, P. R., Saunders, M. J., Harrison, C. J., and Liu Yin, J. A. (1995). Detection of CBFB/MYH11 transcripts in patients with inversion and other abnormalities of chromosome 16 at presentation and remission. Br. J. Haematol. 91, 104-108.
72. van Dongen, J. J. M., Breit, T. M., Adriaansen, H. J., Beishuizen, A., and Hooijkaas, H. (1993). Immunophenotypic and immunogenotypic detection of minimal residual disease in acute lymphoblastic leukemia. Recent Results Cancer Res., Recent Adv. Cell Biol. Acute Leukemia 131, 157-184.
73. Veelken, H., Tycko, B., and Sklar, J. (1991). Sensitive detection of clonal antigen receptor gene rearrangements for the diagnosis and monitoring of lymphoid neoplasms by a polymerase chain reaction-mediated ribonuclease protection assay. Blood 78, 1318-1326.
74. Walker, H., Smith, F. J., and Betts, D. R. (1994). Cytogenetics in acute myeloid leukaemia. Blood Rev. 8, 30-36.
75. Weir, E. G., Cowan, K., LeBeau, P., and Borowitz, M. J. (1999). A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: Implications for residual disease detection. Leukemia 13, 558-567.
76. Westbrook, C. A., Hooberman, L. H., Spino, C., Dodge, R. K., Larsen, R. A., Davey, F., Wurster-Hill, D. H., Sobol, R. E., Schiffer, C., and Bloomfield, C. D. (1992). Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: A cancer and leukemia group B study (8762). Blood 80, 2983-2990.
77. Wörmann, B., Safford, M., Könemann, S., Büchner, T., Hiddemann, W., and Terstappen L. W. M. M. (1993). Detection of aberrant antigen expression in acute myeloid leukemia by multiparameter flow cytometry. Recent Results Cancer Res., Recent Adv. Cell Biol. Acute Leukemia 131, 185-196.
78. Yamada, M., Wasserman, R., Lange, B., Reichard, B. A., Womer, R. B., and Rovera, G. (1990). Minimal residual disease in childhood B-lineage lymphoblastic leukemia. Persistence of leukemic cells during the first 18 months of treatment. N. Engl. J. Med. 323, 448-455.
79. Yokota, S., Hansen-Hagge, T. E., Ludwig, W. D., Reiter, A., Raghavachar, A., Kleihauer, E., and Bartram, C. R. (1991). Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. Blood 77, 331-339.